[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Geneplus-Beijing Co. Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":150},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,65,83,104,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645365","timing-of-ctdna-testing-in-hrher2--advanced-breast-cancer-100645365",false,"NCT07681323","Timing of ctDNA Testing in HR+\u002FHER2- Advanced Breast Cancer","Timing of ctDNA Testing in Advanced Breast Cancer: Impact on Prognosis and Treatment Strategies - A Prospective Observational Study (TIMING)","TIMING","Inclusion Criteria:\n\n* Histologically confirmed advanced breast cancer, molecular subtype HR+\u002FHER2-\n* Age ≥18 years\n* Expected survival \\>3 months\n* Willing to undergo ctDNA testing and sign informed consent form\n\nExclusion Criteria:\n\n* The subject has not signed the informed consent form.\n* Pregnant or breastfeeding women.\n* Other situations deemed by the investigator as unsuitable for inclusion in the study.","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","This multicenter, prospective observational cohort study aims to investigate the impact of ctDNA level and key actionable gene mutation status on prognosis and treatment response in patients with advanced HR+\u002FHER2- breast cancer.",[25],"Advanced Breast Cancer",[27,28,29,30],"ctDNA","multigene testing","HR+\u002FHER2- breast cancer","treatment strategy","NOT_YET_RECRUITING","2026-06-26",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":21},"2026-06-30",{"date":39,"type":21},"2029-06-30",{"name":41,"class":42},"Geneplus-Beijing Co. Ltd.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100523658","circulating-tumor-dna-ctdna-as-a-predictive-biomarker-for-immunotherapy-in-advanced-or-locally-advanced-dmmrmsi-h-colorectal-patients-100523658","NCT06098560","Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR\u002FMSI-H Colorectal Patients","Study on the Clinical Potential of Circulating Tumor DNA in Advanced or Locally Advanced dMMR\u002FMSI-H Colorectal Patients Treated With Immunotherapy","Inclusion Criteria:\n\n\\- advanced or locally advanced dMMR\u002FMSI-H colorectal cancer Expected to receive\u002Fbe receiving immune checkpoint inhibitor therapy ECOG performance score is 0-1, life expectancy ≥12 weeks\n\nExclusion Criteria:\n\n\\- The presence of other uncured malignancies Patients with one or more serious concomitant systemic diseases that, in the investigator's opinion, impair the patient's ability to complete the study Patients with autoimmune disease are not suitable for PD1 monoclonal antibody therapy","80 Years",{"count":53,"type":21},60,"dMMR\u002FMSI-H colorectal cancer patients are the dominant population of immunotherapy\u002Fneoadjuvant immunotherapy, but imaging evaluation of immunotherapy efficacy is insufficient. There are some cases, although no disease remission was found on imaging,pathological complete response (pCR) was confirmed after surgery. Meanwhile,previous studies have shown that dynamic changes in ctDNA can help assess immunotherapy efficacy. Therefore, we propose to conduct a multicenter, prospective, observational clinical study to explore the efficacy prediction and monitoring value of ctDNA in immunotherapy for advanced or locally advanced dMMR\u002FMSI-H colorectal cancer.",[56],"Colorectal Cancer","RECRUITING",{"date":37,"type":35},{"date":60,"type":35},"2023-10-30",{"date":62,"type":21},"2026-12",{"name":41,"class":42},2,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":43},"100513445","exploration-of-predictive-markers-of-neoadjuvant-immunotherapy-in-non-small-cell-lung-cancer-100513445","NCT05965557","Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer","A Biomarker Study for Predicting the Response of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Based on Circulating Tumor DNA and Homologous Recombination Deficiency Analysis","Inclusion Criteria:\n\n* Stage II-IIIB NSCLC\n* EGFR\u002FALK negative\n* The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up\n\nExclusion Criteria:\n\n* A history of other malignancies within the past 5 years\n* Patients with autoimmune disease are not suitable for PD1 monoclonal antibody therapy",{"count":73,"type":21},100,"Neoadjuvant immunotherapy has become the standard perioperative treatment in lung cancer, but its effective predictive biomarkers are lacking. A small cohort reported that homologous recombination deficiency (HRD) can be used as a reliable biomarker to predict the efficacy of neoadjuvant immunotherapy, but the findings need to be validated in larger cohorts. Moreover, circulating tumor DNA (ctDNA) has the potential to predict the therapeutic efficacy of neoadjuvant immunotherapy.\n\nThis study intends to prospectively collect patients with driver-negative stage II-IIIB NSCLC who are scheduled to receive neoadjuvant immunotherapy and surgical resection and verify the value of HRD in predicting the efficacy of neoadjuvant immunotherapy. Meanwhile, the blood samples before and after neoadjuvant immunotherapy were collected for high-depth ctDNA detection to explore the correlation between the dynamic changes of ctDNA and the efficacy and prognosis of neoadjuvant immunotherapy.",[76],"Lung Cancer",{"date":37,"type":35},{"date":79,"type":35},"2023-06-19",{"date":81,"type":21},"2027-12",{"name":41,"class":42},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":43},"100583460","application-of-cfdna-methylation-detection-in-auxiliary-diagnosis-of-breast-cancer-100583460","NCT06876610","Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer","Inclusion Criteria for All the Participants:\n\n* With confirmed pathological diagnosis and molecular subtyping results\n* Ability to provide a written informed consent\n\nExclusion Criteria for Cancer Arm Participants:\n\n* Patients with a history of or currently suffering from other malignancies\n* Pregnant or planning to become pregnant female patients\n* Patients who have received cancer treatment, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, before blood draw\n* Patients with a history of blood transfusion within the past month\n* Patients with a known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation\n* Patients with persistent fever or undergoing anti-inflammatory treatment within 14 days before blood draw\n* Any other conditions that the researcher deems may make the patient unsuitable for inclusion in the study or may interfere with the completion of the study\n* Patients in poor physical condition who are not suitable for blood draw\n* Patients who cannot provide informed consent or refuse blood draw\n\nExclusion Criteria for Benign Diseases Arm Participants:\n\n* History of malignancies\n* Current malignancies or precancerous lesions","30 Years","75 Years",{"count":92,"type":21},200,"The purpose of this study is to construct an auxiliary diagnostic model for breast cancer by methylation markers. The study will collect blood and tissue samples from participants with breast cancer and benign disease for whole-genome methylation sequencing. It will screen methylation markers and develop a methylation auxiliary diagnosis model to distinguish between breast cancer and non-cancer.",[95],"Breast Cancer Screening","2025-03-12",{"date":98,"type":35},"2025-03-14",{"date":100,"type":21},"2025-03-15",{"date":102,"type":21},"2026-08-31",{"name":41,"class":42},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":111,"minAge":18,"maxAge":51,"enrollmentInfo":112,"targetDuration":114,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":43},"100537903","the-exploration-of-personalized-ctdna-based-mrd-in-the-clinical-significance-of-cervical-cancer-100537903","NCT06283875","The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer","A Prospective, Single Center Clinical Study on the Clinical Significance of Personalized ctDNA-MRD in Predicting the Efficacy and Monitoring the Risk of Recurrence of Cervical Cancer","Inclusion Criteria:\n\n* (1) Confirmed by histopathology and classified as stage IB-IVA cervical cancer patients according to the 2018 FIGO staging criteria;\n\n  (2) Patients can receive surgical treatment or curative radiotherapy and chemotherapy;\n\n  (3) Age range from 18 to 80 years old;\n\n  (4) General condition: ECOG 0-2;\n\n  (5) At least one measurable lesion (RECIST 1.1 standard);\n\n  (6) Be able to understand the research plan and voluntarily participate in this study, and sign an informed consent form;\n\n  (7) Good compliance, able to cooperate in collecting specimens from various nodes and provide corresponding clinical information;\n\n  (8) Having comprehensive clinical data on imaging and pathology;\n\n  (9) The estimated survival time of the patient is greater than 3 months;\n\n  (10) Having sufficient organ and bone marrow functions.\n\nExclusion Criteria:\n\n* 1\\) Within 5 years, suffering from other malignant tumors or metastatic or recurrent cervical cancer;\n\n  (2) Has received any tumor treatment plan in the past;\n\n  (3) Surgical resection or curative radiotherapy and chemotherapy are not acceptable;\n\n  (4) Unable to follow the determined clinical follow-up period in conjunction with the study for follow-up;\n\n  (5) Inability to accept or provide specified efficacy evaluation methods such as CT;\n\n  (6) Suffering from autoimmune diseases;\n\n  (7) Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders;\n\n  (8) Subjects with any severe and\u002For uncontrolled diseases;\n\n  (9) According to the researchers judgment, there are accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study by the subjects","FEMALE",{"count":113,"type":21},80,"5 Years","This study plans to enroll 80 patients with locally advanced cervical cancer (stage IB-ⅣA) confirmed by histology or cytology (according to the 2018 FIGO staging standard), who are expected to receive surgical resection or curative radiotherapy and chemotherapy. Collect baseline tumor tissue samples from patients during the treatment period, as well as peripheral blood samples (20 ml\u002Ftime) from multiple treatment timepoints. Mutations in tumor tissue were detected by the 1021 genes panel, then personalized MRD monitoring probes were customized for patients, allowing for multi node peripheral blood sample ctDNA detection of enrolled patients. The clinical significance of ctDNA in prognostic stratification, recurrence monitoring, and efficacy prediction in surgical\u002Fnon-surgical cervical cancer patients was explored. And compare the consistency and differences between ctDNA detection technology, imaging, and blood tumor markers in monitoring tumor disease progression, and evaluate the correlation between ctDNA status after curative treatment and patient PFS and RFS.",[117],"Ovarian Cancer",[27,119,120,121,122,123,124],"MRD","cervical carcinoma","operation","Radical radiotherapy and chemotherapy","Efficacy prediction","Recurrence monitoring","2024-07-16",{"date":127,"type":35},"2024-07-18",{"date":129,"type":21},"2024-12-01",{"date":131,"type":21},"2029-01-30",{"name":41,"class":42},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":43},"100389644","ctdna-monitoring-in-early-breast-cancer-100389644","NCT04353557","ctDNA Monitoring in Early Breast Cancer","Monitoring Circulating Tumor DNA in Patients With Early Stage Breast Cancer","Inclusion Criteria:\n\n1. Patients aged 18 to 80 years old\n2. Histologically proven primary breast cancer with clinical stage I-III\n3. Patients with neoadjuvant therapy, and\u002For radical surgery\u002Fbreast conserving surgery, adjuvant chemotherapy and target therapy (Her2+), radiotherapy (if indicated).\n4. Expected to achieve R0 resection.\n5. Estimated lifetime is more than 3 months.\n6. Signed Informed Consent Form\n7. Consent to provide research blood samples.\n\nExclusion Criteria:\n\n1. Patients intended to receive adjuvant chemotherapy with Eastern Cooperative Oncology Group (ECOG) performance status 3, 4 or 5.\n2. Patients intended to receive postoperative radiotherapy with Eastern Cooperative Oncology Group (ECOG) performance status 5.\n3. Prior diagnosis of cancer in the previous 5 years, other than for basal cell carcinoma of the skin or cervical carcinoma in situ.\n4. Presence of any systemic illness incompatible with participation in the clinical trial or inability to provide written informed consent.",{"count":92,"type":21},"This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in patients with early breast cancer and assessing the prognostic value and treatment outcome monitoring of ctDNA.",[143],"Breast Cancer",[27],{"date":127,"type":35},{"date":147,"type":35},"2019-11-29",{"date":62,"type":21},{"name":41,"class":42},""]